The Employers' Union of Innovative Pharmaceutical Companies
Budget
€50 — €0
EP Access
0
accredited persons
Staff
2
0.2 FTE
EU Grants
None
Mission & Goals
The Employers' Union of Innovative Pharmaceutical Companies INFARMA represents 24 leading pharmaceutical companies engaged in research and development activities and the production of innovative medicines. INFARMA’s objective is taking initiatives which positively influence the creation of system solutions in the field of healthcare and promoting innovation resulting from research and original medicinal products in accordance with the principles of medicine based on evidence. Such solutions should allow patients access to modern and the most effective treatments so that Polish norms of treatment meet the global standards. In particular, it aims to foster an environment that encourages pharmaceutical research and development, manufacture in compliance with high-quality standards, intellectual property protection and the introduction of regulatory requirements to allow patients rapid access to medicinal products.
EU Legislative Interests
Any health or pharmaceutical policy stemming from the European institutions, such as - but not exclusive - Industrial Policy, Pharmaceutical Strategy, pharmaceutical, orphan and paediatrics legislation, Horizon Europe Research Programme, HTA policy, IP policy, One Health Approach to tackle AMR, COVID-19 outbreak measures. Main EU legislative proposals or policies targeted (a non-exhaustive list): - A Pharmaceutical Strategy for Europe – over 50 legislative and non-legislative proposals - Directive 2001/83/EC on the Community code relating to medicinal products for human use - Regulation (EC) No 726/2004 of the European Parliament and of the Council laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency - Regulation (EC) No 141/2000 of the European Parliament and of the Council on orphan medicinal products. - Regulation (EC) No 1901/2006 of the European Parliament and of the Council on medicinal products for paediatric use In addition, we also follow for example: - Clinical Trial Regulation - EMA Fees Regulation - Europe’s Beating Cancer Plan - European Health Data Space - HERA Regulation - SPCs Regulation revision - IP Action Plan
Communication Activities
INFARMA communications activities include: - Publishing new evidence (etc. reports, leaflets, infographics) - Preparing and communicating letters, information material or discussion papers and position papers, - Organising events, meetings, promotional activities, conferences or social events, - Disseminating our key messages through media and social media, - Participation in formal consultations or hearings in the EU legislative.
Interests Represented
Promotes their own interests or the collective interests of their members
Member Of
European Federation of Pharmaceutical Industries and Associations https://www.efpia.eu/ Employers of Poland https://pracodawcyrp.pl/ National Chamber of Commerce https://kig.pl/
Organisation Members
National Medicines Verification System Foundation https://www.nmvo.pl/en/
Commissioner Meetings
No recorded meetings with EU commissioners.